PHGDH and non-small cell lung carcinoma: This finding suggests that targeting these genes could potentially restore the efficacy of chemotherapy in drug‐resistant NSCLC (Figure 4B).[35, 36, 37, 101, 105] Furthermore, CRISPR‐screening technology was utilized to identify phosphoglycerate dehydrogenase (PHGDH) as a suspected drug‐resistance gene against sorafenib for hepatocellular carcinoma.